These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 25525051)

  • 1. Randomized, controlled trial of high-dose influenza vaccine among frail residents of long-term care facilities.
    Nace DA; Lin CJ; Ross TM; Saracco S; Churilla RM; Zimmerman RK
    J Infect Dis; 2015 Jun; 211(12):1915-24. PubMed ID: 25525051
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of Two High-Dose Versus Two Standard-Dose Influenza Vaccines in Adult Allogeneic Hematopoietic Cell Transplant Recipients.
    Thomas LD; Batarseh E; Hamdan L; Haddadin Z; Dulek D; Kalams S; Stewart LS; Stahl AL; Rahman H; Amarin JZ; Hayek H; Ison M; Overton ET; Pergam SA; Spieker AJ; Halasa NB;
    Clin Infect Dis; 2023 Dec; 77(12):1723-1732. PubMed ID: 39219510
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influenza Vaccine-Induced Antibody Responses Are Not Impaired by Frailty in the Community-Dwelling Elderly With Natural Influenza Exposure.
    Narang V; Lu Y; Tan C; Camous XFN; Nyunt SZ; Carre C; Mok EWH; Wong G; Maurer-Stroh S; Abel B; Burdin N; Poidinger M; Tambyah PA; Bosco N; Visan L; Ng TP; Larbi A
    Front Immunol; 2018; 9():2465. PubMed ID: 30405641
    [No Abstract]   [Full Text] [Related]  

  • 4. The Durability of Antibody Responses of Two Doses of High-Dose Relative to Two Doses of Standard-Dose Inactivated Influenza Vaccine in Pediatric Hematopoietic Cell Transplant Recipients: A Multi-Center Randomized Controlled Trial.
    Schuster JE; Hamdan L; Dulek DE; Kitko CL; Batarseh E; Haddadin Z; Stewart LS; Stahl A; Potter M; Rahman H; Kalams SA; Bocchini CE; Moulton EA; Coffin SE; Ardura MI; Wattier RL; Maron G; Grimley M; Paulsen G; Harrison CJ; Freedman JL; Carpenter PA; Englund JA; Munoz FM; Danziger-Isakov L; Spieker AJ; Halasa NB;
    Clin Infect Dis; 2024 Jan; 78(1):217-226. PubMed ID: 37800415
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical trial to evaluate the safety and immunogenicity of a trivalent surface antigen seasonal influenza vaccine produced in mammalian cell culture and administered to young and elderly adults with and without A(H1N1) pre-vaccination.
    Loebermann M; Voss U; Meyer S; Bosse D; Fritzsche C; Klammt S; Frimmel S; Riebold D; Reisinger EC
    PLoS One; 2013; 8(8):e70866. PubMed ID: 23976960
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serological response to influenza A H1N1 vaccine (Pandemrix®) and seasonal influenza vaccine 2009/2010 in renal transplant recipients and in hemodialysis patients.
    Ott U; Sauerbrei A; Lange J; Schäfler A; Walther M; Wolf G; Wutzler P; Zell R; Krumbholz A
    Med Microbiol Immunol; 2012 Aug; 201(3):297-302. PubMed ID: 22350187
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Benefits of increasing the dose of influenza vaccine in residents of long-term care facilities: a randomized placebo-controlled trial.
    Cools HJ; Gussekloo J; Remmerswaal JE; Remarque EJ; Kroes AC
    J Med Virol; 2009 May; 81(5):908-14. PubMed ID: 19319953
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Kinetics of the antibody response to seasonal influenza vaccination among the elderly.
    Kositanont U; Assantachai P; Wasi C; Puthavathana P; Praditsuwan R
    Viral Immunol; 2012 Dec; 25(6):471-6. PubMed ID: 23061793
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serologic response to sequential vaccination with enhanced influenza vaccines: Open label randomized trial among adults aged 65-74 years.
    McLean HQ; Levine MZ; King JP; Flannery B; Belongia EA
    Vaccine; 2021 Dec; 39(49):7146-7152. PubMed ID: 34774360
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and immunogenicity of high-dose trivalent inactivated influenza vaccine in adults 50-64 years of age.
    DiazGranados CA; Saway W; Gouaux J; Baron M; Baker J; Denis M; Jordanov E; Landolfi V; Yau E
    Vaccine; 2015 Dec; 33(51):7188-7193. PubMed ID: 26555348
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized, single-blind, active-controlled phase I clinical trial to evaluate the immunogenicity and safety of GC3114 (high-dose, quadrivalent influenza vaccine) in healthy adults.
    Noh JY; Jang YS; Lee SN; Choi MJ; Yoon JG; Yu DH; Song JY; Cheong HJ; Kim WJ
    Vaccine; 2019 Aug; 37(36):5171-5176. PubMed ID: 31377075
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influenza vaccine immunogenicity in 6- to 23-month-old children: are identical antigens necessary for priming?
    Walter EB; Neuzil KM; Zhu Y; Fairchok MP; Gagliano ME; Monto AS; Englund JA
    Pediatrics; 2006 Sep; 118(3):e570-8. PubMed ID: 16950948
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intradermally-administered influenza virus vaccine is safe and immunogenic in healthy adults 18-64 years of age.
    Gorse GJ; Falsey AR; Fling JA; Poling TL; Strout CB; Tsang PH
    Vaccine; 2013 May; 31(19):2358-65. PubMed ID: 23499604
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Randomized Trial of Two 2-Dose Influenza Vaccination Strategies for Patients Following Autologous Hematopoietic Stem Cell Transplantation.
    Teh BW; Leung VKY; Mordant FL; Sullivan SG; Joyce T; Harrison SJ; Khvorov A; Barr IG; Subbarao K; Slavin MA; Worth LJ
    Clin Infect Dis; 2021 Dec; 73(11):e4269-e4277. PubMed ID: 33175132
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of Previous-Season Influenza Vaccination on Serologic Response in Children During 3 Seasons, 2013-2014 Through 2015-2016.
    McLean HQ; King JP; Talley P; Flannery B; Spencer S; Levine MZ; Friedrich TC; Belongia EA
    J Pediatric Infect Dis Soc; 2020 Apr; 9(2):173-180. PubMed ID: 30759228
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunization with trivalent inactivated influenza vaccine in partially immunized toddlers.
    Englund JA; Walter EB; Gbadebo A; Monto AS; Zhu Y; Neuzil KM
    Pediatrics; 2006 Sep; 118(3):e579-85. PubMed ID: 16950949
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized, double-blind noninferiority study of quadrivalent live attenuated influenza vaccine in adults.
    Block SL; Yi T; Sheldon E; Dubovsky F; Falloon J
    Vaccine; 2011 Nov; 29(50):9391-7. PubMed ID: 21983154
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antibody response to influenza vaccination in nursing home residents and healthcare workers during four successive seasons in Niigata, Japan.
    Sato M; Saito R; Tanabe N; Nishikawa M; Sasaki A; Gejyo F; Suzuki H
    Infect Control Hosp Epidemiol; 2005 Nov; 26(11):859-66. PubMed ID: 16323321
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cell-Mediated Immune Responses After Influenza Vaccination of Solid Organ Transplant Recipients: Secondary Outcomes Analyses of a Randomized Controlled Trial.
    L'huillier AG; Ferreira VH; Hirzel C; Natori Y; Slomovic J; Ku T; Hoschler K; Ierullo M; Selzner N; Schiff J; Singer LG; Humar A; Kumar D
    J Infect Dis; 2020 Jan; 221(1):53-62. PubMed ID: 31550354
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunogenicity and safety of Fluzone(®) intradermal and high-dose influenza vaccines in older adults ≥65 years of age: a randomized, controlled, phase II trial.
    Tsang P; Gorse GJ; Strout CB; Sperling M; Greenberg DP; Ozol-Godfrey A; DiazGranados C; Landolfi V
    Vaccine; 2014 May; 32(21):2507-17. PubMed ID: 24120672
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.